Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fortress Biotech

1.83
+0.08004.57%
Post-market: 1.81-0.0200-1.09%19:30 EDT
Volume:205.23K
Turnover:371.21K
Market Cap:54.05M
PE:-0.68
High:1.86
Open:1.75
Low:1.75
Close:1.75
Loading ...

Fortress Biotech, Partex Team Up for Asset Identification, Evaluation Using AI

MT Newswires Live
·
17 Mar

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

THOMSON REUTERS
·
17 Mar

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

GlobeNewswire
·
17 Mar

Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Reuters
·
15 Mar

BUZZ-India's Sun Pharma set for best week in nearly 6 months after Checkpoint deal

Reuters
·
13 Mar

Fortress Biotech Price Target Raised to $16.00/Share From $15.00 by Roth MKM

Dow Jones
·
11 Mar

Fortress Biotech price target raised to $16 from $15 at Roth MKM

TIPRANKS
·
11 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group

Reuters
·
11 Mar

India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details

Benzinga
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Primo Brands, Cracker Barrel, Redfin

Reuters
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Airbnb, Beacon, Redfin

Reuters
·
10 Mar

BUZZ-Checkpoint Therapeutics rises on $355 million Sun Pharma buyout deal

Reuters
·
10 Mar

Deals of the day-Mergers and acquisitions

Reuters
·
10 Mar

Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical

MT Newswires Live
·
10 Mar

India’s Sun Pharma to buy Checkpoint Therapeutics for $355 mln

Investing.com
·
10 Mar

INDIA STOCKS-Indian stocks set for muted start after last week's gains

Reuters
·
10 Mar

India's Sun Pharma to acquire Checkpoint Therapeutics

Reuters
·
10 Mar

Sun Pharma to Acquire Checkpoint Therapeutics

PR Newswire
·
10 Mar

BRIEF-Journey Medical Corporation Announces Publication In The Journal Of The American Medical Association - Dermatology Of The Phase 3 Clinical Trial Results Of Emrosi™ (Dfd-29) To Treat Rosacea

Reuters
·
06 Mar

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

GlobeNewswire
·
06 Mar